Presence of a BRAF V600E mutation, the most common driver mutation in the spectrum of follicular cell derived thyroid cancers, can confer susceptibility to selective RAF kinase inhibitors in some cancer lineages. Here, BRAF is linked to thyroid gland carcinoma.